Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIMBLE: Pozelimab and Cemdisiran in Generalized Myasthenia Gravis
NCT05070858Phase 3Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Jul 2025
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 19
01
Overview
A Phase 3 trial of pozelimab, cemdisiran in myasthenia gravis (MG), sponsored by Regeneron Pharmaceuticals. Started Dec 2021; status: active, not recruiting.
02
Drugs
pozelimabcemdisiran
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05070858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070858.